Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E14.98 EPS (ttm)3.16 Insider Own0.10% Shs Outstand1.65B Perf Week0.38%
Market Cap77.82B Forward P/E10.74 EPS next Y4.41 Insider Trans0.12% Shs Float1.63B Perf Month6.01%
Income5.17B PEG2.93 EPS next Q1.06 Inst Own79.50% Short Float5.60% Perf Quarter-7.22%
Sales23.29B P/S3.34 EPS this Y28.70% Inst Trans5.54% Short Ratio5.03 Perf Half Y-11.56%
Book/sh9.31 P/B5.08 EPS next Y5.05% ROA15.10% Target Price57.30 Perf Year-9.63%
Cash/sh5.33 P/C8.88 EPS next 5Y5.12% ROE37.30% 52W Range44.30 - 63.69 Perf YTD-9.00%
Dividend1.64 P/FCF29.81 EPS past 5Y14.50% ROI25.40% 52W High-25.73% Beta0.74
Dividend %3.47% Quick Ratio1.80 Sales past 5Y6.60% Gross Margin71.10% 52W Low6.77% ATR0.93
Employees23300 Current Ratio1.90 Sales Q/Q14.00% Oper. Margin27.80% RSI (14)52.28 Volatility1.55% 1.89%
OptionableYes Debt/Eq0.40 EPS Q/Q12.90% Profit Margin22.10% Rel Volume0.59 Prev Close47.74
ShortableYes LT Debt/Eq0.37 EarningsApr 25 BMO Payout51.10% Avg Volume18.20M Price47.30
Recom2.20 SMA200.93% SMA500.36% SMA200-9.99% Volume10,834,482 Change-0.92%
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
May-24-19 06:59AM  Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire
May-23-19 04:15PM  Synlogic (SYBX) Enters Cancer Collaboration with Roche Zacks
03:46PM  Novartis Reports Data on Asthma Drug, Update from Annual Meet Zacks
May-22-19 05:13PM  Array BioPharma Gains on Colorectal Cancer Study Success Zacks
03:42PM  Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS Zacks
12:38PM  Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond Benzinga
09:37AM  Merck to Buy Private Cancer Drugmaker Peloton Therapeutics Zacks
07:00AM  Bristol-Myers Stock Continues to Slump, but Director Ted Samuels Is Buying Up Shares
May-21-19 08:13AM  Merck agrees $1bn deal to buy biopharmaceutical company Peloton Financial Times
May-20-19 06:32PM  4 New Stock Picks From Seth Klarman
02:28PM  Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines Benzinga
12:31PM  Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch
09:16AM  Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense
May-17-19 05:19PM  Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL Zacks
05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
May-16-19 04:15PM  Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019 Business Wire
02:15PM  Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only
01:01AM  Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference GlobeNewswire
May-15-19 09:27AM  Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer Zacks
May-14-19 06:11PM  Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition CNBC
04:31PM  These Sleepy Stocks Have Done Nothing, But May Wake Up
10:00AM featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers Zacks
07:15AM  Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What Its Like to Live with Cancer Today Business Wire
06:59AM  Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference Business Wire
May-13-19 01:03PM  Why Bristol-Myers Squibb's $19 Billion Debt Issuance to Buy Celgene Makes Sense
08:50AM  Buy These 5 Stocks With Impressive Sales Growth Right Away Zacks
08:45AM  Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why Zacks
May-11-19 02:51AM  AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks
May-10-19 03:29PM  AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks
02:41PM  Endo (ENDP) Q1 Earnings & Revenues Beat Estimates Zacks
08:23AM  Can Bristol-Myers Squibb Company's (NYSE:BMY) ROE Continue To Surpass The Industry Average? Simply Wall St.
May-09-19 02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
01:28PM  Why this former health care CEO thinks this Uber board member is crucial to its success Yahoo Finance Video
10:21AM featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems Zacks
10:07AM  Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study Benzinga
09:15AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio Zacks
07:39AM  Bristol-Myers' Opdivo fails late-stage brain cancer trial Reuters
06:59AM  Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme Business Wire
May-08-19 04:31PM  IBM Gets a Tepid Reception for Its $20 Billion Bond Sale
04:00PM  Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View Zacks
02:45PM  Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates Zacks
12:06PM  Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates Zacks
09:56AM  Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates Zacks
09:46AM  Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks
09:33AM  Infinity (INFI) Earnings and Sales Miss Estimates in Q1 Zacks
08:51AM  Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss Zacks
07:46AM  5 ROE Stocks to Profit as Trade Woes Shake Equity Markets Zacks
07:33AM  5 Stocks With Upgraded Broker Ratings Worth Betting on Now Zacks
07:00AM  Market Morning: Mylan Massacre, Futures Dither, Meatless McDonalds, Uber Drivers Bash Greed, Want More Money Market Exclusive
06:59AM  Bristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes Business Wire
06:42AM  Bet on Top Stocks With Rising P/E to Enjoy Solid Gains Zacks
06:30AM  Should Investors Worry About Corporate Debt? It Depends on Who You Ask.
May-07-19 05:46PM  Bristol-Myers Borrows $19 Billion in Year's Biggest Bond Deal Bloomberg
04:12PM  What Comes After 2019s Biggest Bond Deal? A Big Debt Diet Bloomberg
01:54PM  Bristol-Myers Squibb Is Selling $19 Billion of Bonds to Buy Celgene
09:35AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
08:58AM  Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1? Zacks
08:05AM  Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss Zacks
02:59AM  Bristol-Myers Squibb in $19bn debt sale to fund Celgene deal Financial Times
May-05-19 12:29PM  Need to know: Max grounding costs mount, an Elysian remake and the story behind an Escala penthouse American City Business Journals
May-03-19 01:08PM  Bristol-Myers Acquisition of Celgene Is a Prescription for Success, One Analyst Says
06:00AM  Seattle life sciences industry has strength in numbers despite uncertainty American City Business Journals
May-02-19 06:28PM  Cramer reviews the top activist stories of 2019: eBay, Dollar Tree, Bristol-Myers, and Bed Bath & Beyond CNBC
12:08PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade Moody's
11:21AM  Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1 Zacks
10:42AM  The Zacks Analyst Blog Highlights: FirstEnergy, Synchrony Financial, ExxonMobil, Morgan Stanley and Bristol-Myers Zacks
May-01-19 09:06PM  Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes Business Wire
06:00PM  The top 2 health care names to play for a catch-up: Technician CNBC Videos
05:46PM  Bristol-Myers Squibb Company Announces Launch of Private Offering of Senior Unsecured Notes Business Wire
02:56PM  Top Research Reports for ExxonMobil, Morgan Stanley & Bristol-Myers Zacks
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
06:56PM  Puerto Rico board files flurry of lawsuits ahead of claim deadline Reuters
03:18PM  Trump, Democratic leaders to meet on drug prices soon -White House Reuters
10:53AM  The 10 Best Health Care Stocks to Buy for 2019 Kiplinger
Apr-29-19 03:19PM  Celgene's Final Earnings Report? Motley Fool
01:08PM  52-Week Company Lows
11:29AM  3 Stocks Peter Lynch Would Love Motley Fool
Apr-27-19 10:39PM  Stocks That Fell to 3-Year Lows in the Week of April 26
11:29AM  Biosimilar competition to AbbVies Humira is eroding profits, but company says it has confidence in pipeline MarketWatch
Apr-26-19 05:36PM  2 Large Drug Manufacturers Release 1st-Quarter Results
02:20PM  Edited Transcript of BMY earnings conference call or presentation 25-Apr-19 2:30pm GMT Thomson Reuters StreetEvents
01:44PM  Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY) Zacks
Apr-25-19 04:06PM  These Pharmas Beat First-Quarter Forecasts; But Biosimilars Rankled One Investor's Business Daily
02:52PM  Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis Zacks
02:45PM  Bristol-Myers Squibb Co (BMY) Q1 2019 Earnings Call Transcript Motley Fool
01:26PM  Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat InvestorPlace
01:03PM  Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming Motley Fool
10:08AM  Pfizer Stock Has Positive and Negative Catalysts Going Into Results InvestorPlace
09:55AM  Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks
09:48AM  Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval
09:42AM  Exelixis (EXEL) to Report Q1 Earnings: What's in Store? Zacks
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
07:55AM  Bristol-Myers: 1Q Earnings Snapshot Associated Press
07:32AM  3 Big Stock Charts for Thursday: Discovery, Norfolk Southern and Bristol-Myers Squibb InvestorPlace
07:11AM  Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters
07:00AM  Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters
06:59AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
06:30AM  Bristol-Myers Squibb Reports Earnings Today. Heres What to Expect.
05:33AM  Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM